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IMPORTANCE Genital herpes simplex virus (HSV) infection is a prevalent sexually transmitted
infection. Vertical transmission of HSV can lead to fetal morbidity andmortality.
OBJECTIVE To assess the evidence on serologic screening and preventive interventions for
genital HSV infection in asymptomatic adults and adolescents to support the US Preventive
Services Task Force for an updated recommendation statement.
DATA SOURCES MEDLINE, Cochrane Library, EMBASE, and trial registries throughMarch 31,
2016. Surveillance for new evidence in targeted publications was conducted through
October 31, 2016.
STUDY SELECTION English-language randomized clinical trials (RCTs) comparing screening
with no screening in persons without past or current symptoms of genital herpes; studies
evaluating accuracy and harms of serologic screening tests for HSV-2; RCTs assessing
preventive interventions in asymptomatic persons seropositive for HSV-2.
DATA EXTRACTION AND SYNTHESIS Dual review of abstracts, full-text articles, and study
quality; pooled sensitivities and specificities of screening tests using a hierarchical summary
receiver operating characteristic curve analysis when at least 3 similar studies were available.
MAIN OUTCOMES ANDMEASURES Accuracy of screening tests, benefits of screening, harms of
screening, reduction in genital herpes outbreaks.
RESULTS A total of 17 studies (n = 9736 participants; range, 24-3290) in 19 publications were
included. No RCTs compared screening with no screening. Most studies of the accuracy of
screening tests were from populations with high HSV-2 prevalence (greater than 40% based
onWestern blot). Pooled estimates of sensitivity and specificity of themost commonly used
test at themanufacturer’s cutpoint were 99% (95% CI, 97%-100%) and 81% (95% CI,
68%-90%), respectively (10 studies; n = 6537). At higher cutpoints, pooled estimates were
95% (95% CI, 91%-97%) and 89% (95% CI, 82%-93%), respectively (7 studies; n = 5516).
Use of this test at themanufacturer’s cutpoint in a population of 100000with a prevalence
of HSV-2 of 16% (the seroprevalence in US adults with unknown symptom status) would
result in 15 840 true-positive results and 15 960 false-positive results (positive predictive
value, 50%). Serologic screening for genital herpes was associated with psychosocial harms,
including distress and anxiety related to positive test results. Four RCTs compared preventive
medications with placebo, 2 in nonpregnant asymptomatic adults who were HSV-2
seropositive and 2 in HSV-2–serodiscordant couples. Results in both populations were
heterogeneous and inconsistent.
CONCLUSIONS AND RELEVANCE Serologic screening for genital herpes is associated with a
high rate of false-positive test results and potential psychosocial harms. Evidence from RCTs
does not establish whether preventive antiviral medication for asymptomatic HSV-2 infection
has benefit.
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G enitalherpes isasexually transmitted infection(STI)causedby herpes simplex virus (HSV) type 1 or type 2. Many pa-tients experience signs and symptoms during primary in-
fectionand recurrences, but somemayhavemildorno symptoms.1
Episodic subclinical viral shedding leads to the potential for trans-
mission in the absence of symptoms.2,3 HSV-2 accounts for most
prevalent genital herpes cases and is more likely to cause frequent
symptomatic recurrences thanHSV-1 (which ismost commonly ac-
quired in childhood and associated with orofacial infection).4-6
GenitalHSVinfectionduringpregnancyposesariskofneonatal trans-
missionduringdelivery,particularlyamongwomenwhoacquireHSV
near the time of delivery.1,7
The true prevalence of asymptomatic HSV-2 infection is un-
known; prevalence estimates rely on serologic test results and are
not confirmedwithWesternblot. The estimated seroprevalenceof
HSV-2 in the United States was 16% in 2005-2010; only 14%of se-
ropositive persons reported having been diagnosed with genital
herpes.6 It is unclear what proportion of HSV-2–seropositive par-
ticipants with no prior diagnosis of genital herpes had true asymp-
tomatic (or unrecognized) infection vs a false-positive test result.
In theory, screening to identify unrecognized HSV-2 infection
followed by counseling, antiviral treatment (episodic or sup-
pressive), or both could prevent transmission and reduce symp-
toms and shedding. Several US Food and Drug Administration
(FDA)–approved type-specific HSV serologic tests are available.8
Since HSV-2 rarely causes infection outside the anogenital region,
HSV-2 antibodies can be interpreted as an indicator of genital
infection.
In 2005, the US Preventive Services Task Force (USPSTF) rec-
ommended against routine serologic screening for HSV in asymp-
tomatic adolescents, adults, and pregnant women (grade D
recommendation).9To informanupdated recommendation,we re-
viewed the evidence on benefits and harms of serologic screening
for HSV-2, screening test accuracy, and benefits and harms of anti-
viral treatment in populations relevant to US primary care.
Methods
Scope of Review
Detailed methods are available in the full evidence report at
https://www.uspreventiveservicestaskforce.org/Page/Document
/final-evidence-review/genital-herpes-screening1. The full evi-
dence report also provides additional information about the pro-
posedmethods for keyquestion (KQ) 7 (focusedon theassociation
between subclinical genital HSV-2 viral shedding and health out-
comes), additional background and contextual information about
genital herpes in the United States, and a list of studies that were
excluded during the full-text review phase of the literature search.
Figure 1 shows the analytic framework and KQs that guided
the review.
Data Sources and Searches
PubMed/MEDLINE, the Cochrane Library, and EMBASE were
searched for English-language articles published through March
31, 2016. Search strategies are listed in eMethods in the Supple-
ment. We searched for unpublished literature in ClinicalTrials.gov
and the World Health Organization’s International Clinical Trials
Registry Platform. To supplement electronic searches, reference
lists of pertinent articles and suggested citations from reviewers
were reviewed. We conducted ongoing surveillance after March
2016 through article alerts and targeted searches of high-impact
journals to identify major studies published in the interim that
may affect the conclusions or understanding of the evidence and
related USPSTF recommendation. The last surveillance was con-
ducted on October 31, 2016.
Study Selection
Two investigators independently reviewed titles, abstracts, and
full-text articles to determine eligibility using prespecified criteria
(eTable 1 in the Supplement). Disagreements were resolved by dis-
cussion. English-language studies of immunocompetent adults or
adolescents, including pregnant women, were included. Only stud-
ies rated as good or fair quality were included. For all KQs, studies
of persons without symptoms or a clinical history of genital herpes
were eligible, as were studies of asymptomatic partners of persons
with known genital herpes (ie, discordant couples). For the over-
arching question on direct evidence that screening improves health
outcomes (KQ1), only randomized clinical trials (RCTs) comparing
groups that were screened with groups that were not screened
were included.
For KQ2 (accuracy of serologic tests), we included studies of
FDA-approvedserologic tests forHSV-2that reportedaccuracycom-
pared with the Western blot, which has been used as a reference
standard in studies assessing commercially available serologic tests
in the United States. Eligible populations could be symptomatic,
asymptomatic, or a combination of both.
ForKQ3 (harmsof screening),we included trials, systematic re-
views, and observational studies assessing the harms of screening
in asymptomatic populationswith noprior diagnosis of genital her-
pes, with or without a comparison group.
For studies assessing benefits or harms of preventive medica-
tions in asymptomatic populations (KQ4 through KQ6), RCTs
comparing FDA-approved oral antiviral medications for the sup-
pression of recurrent genital herpes (acyclovir, famciclovir, or
valacyclovir) with placebo were eligible. RCTs of behavioral coun-
seling interventions (eg, education or counseling; partner notifi-
cation; barrier protection; or combinations of these components)
were also eligible. For studies assessing the harms of antiviral
medications in pregnant women (KQ6b), multi-institution antivi-
ral medication pregnancy exposure registries were eligible. Eli-
gible outcomes included reduced rates of symptomatic episodes
and transmission (including measures of HSV-2 seroconversion).
For KQ5b (effectiveness of interventions in pregnant women), eli-
gible outcomes also included rates of neonatal HSV infection and
reduced rates of symptomatic genital herpes at delivery. For KQ4
(effects of antiviral medication on subclinical HSV-2 shedding),
we included any outcome measure of subclinical HSV-2 shedding
(eg, percentage of days with any shedding detected).
Data Extraction andQuality Assessment
For each included study, one investigator extracted information
about design, population, tests or treatments used, andoutcomes,
and a second investigator reviewed for completeness and accu-
racy. Two independent investigators assessed the quality of each
study as good, fair, or poor, using predefined criteria developed by
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the USPSTF and adapted for this topic (eTables 2-3 in the Supple-
ment). Individual study quality ratings are provided in the
Supplement (eTables 4-7).
Data Synthesis and Analysis
Findings for each question were summarized in tabular and narra-
tive form. To determine whether meta-analyses were appropriate,
the clinical and methodological heterogeneity of the studies was
assessed following established guidance.11 To do this, we qualita-
tively assessed the similarities and differences in populations,
tests, treatments, comparators, outcomes, and designs. For KQ2
(the only KQ with sufficient numbers of similar studies for quanti-
tative syntheses), pooled sensitivities and specificities for each
type of serologic test were calculated using a hierarchical sum-
mary receiver operating characteristic (HSROC) curve analysis
when at least 3 similar studies were available. Separate models
Figure 1. Analytic Framework and Key Questions
Key questions
5 a. How effective are preventive medications and behavioral counseling interventions in reducing future symptomatic episodes and transmissions of
genital herpes in asymptomatic nonpregnant adults and adolescents?
b. How effective are preventive medications and behavioral counseling interventions in reducing neonatal HSV infection and symptomatic episodes
of genital herpes at delivery in pregnant women?
6 a. What are the harms of preventive medications and behavioral counseling interventions for reducing future symptomatic episodes and transmission
of genital herpes in asymptomatic nonpregnant adults and adolescents?
b. What are the harms of preventive medications and behavioral counseling interventions for reducing neonatal HSV infection and symptomatic
episodes of genital herpes at delivery in asymptomatic pregnant women?
1 a. Does serologic screening for herpes simplex virus type 2 (HSV-2) or combined testing for herpes simplex virus type 1 (HSV-1) and 2 in asymptomatic
nonpregnant adults and adolescents reduce future symptomatic episodes and transmission of genital herpes?
b. Does serologic screening for HSV-2 or combined testing for HSV-1 and HSV-2 in pregnant women reduce neonatal HSV infection and symptomatic
episodes of genital herpes at delivery?
3 a. What are the harms of serologic screening for HSV-2 or combined testing for HSV-1 and HSV-2 in asymptomatic nonpregnant adolescents and adults?
b. What are the harms of serologic screening for HSV-2 or combined testing for HSV-1 and HSV-2 in asymptomatic pregnant women?
What is the accuracy of serologic screening for HSV-2 in asymptomatic adults, adolescents, and pregnant women?2
What is the evidence supporting an association between subclinical HSV-2 viral shedding and health outcomes in asymptomatic adults, adolescents,
and pregnant women who are seropostive for HSV-2?
7
How effective are oral antiviral medications in reducing genital HSV-2 viral shedding in asymptomatic adolescents, adults, and pregnant women?4
Harms of
screening
3
HSV serologic
screening a
Preventive
medications
and behavioral
counseling
Health outcomes
Genital herpes symptoms
Transmission of genital herpes
Neonatal HSV infection
1
5
Asymptomatic sexually
active adults, adolescents,
and pregnant women with
no clinical history of
genital herpes
2
Harms of
interventions
6
4HSV status Genital HSV-2
viral shedding
7b
Evidence reviews for the US Preventive Services Task Force (USPSTF) use an
analytic framework to visually display the key questions that the reviewwill
address to allow the USPSTF to evaluate the effectiveness and safety of a
preventive service. The questions are depicted by linkages that relate
interventions and outcomes. A dashed line indicates health outcomes that
follow an intermediate outcome. HSV indicates herpes simplex virus. Further
details are available from the USPSTF procedure manual.10
a Studies that screen using an HSV-2 serologic test alone or a paired (HSV-1 and
HSV-2) serologic test will be included if theymeet other eligibility criteria;
however, only the accuracy of test characteristics related to HSV-2 serologic
tests will be evaluated.
bKey question 7 will be addressed only if there is insufficient literature for key
questions 1 and 5 but sufficient literature for key question 4.
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were developed for each type of serologic test, and separate
analyses were conducted for HerpeSelect using the manufacturer-
recommended cutpoint for test positivity and for higher cutpoints
reported in the literature to determine whether accuracy is
improved with using higher cutpoints. The metandi program in
Stata version 1412 was used to conduct all quantitative analyses.
Results
Seventeen includedstudieswitha total of9736participants (range,
24-3290) and reported in 19 publications were identified
(Figure 2).13-29
Benefits of Screening
Key Question 1a. Does serologic screening for HSV-2 or combined
testing forHSV-1andHSV-2 inasymptomaticnonpregnantadultsand
adolescents reduce future symptomatic episodes and transmis-
sion of genital herpes?
Key Question 1b. Does serologic screening for HSV-2 or combined
testing forHSV-1andHSV-2 inpregnantwomenreduceneonatalHSV
infection and symptomatic episodes of genital herpes at delivery?
No eligible studies were identified.
Accuracy of HSV-2 Serologic Screening Tests
KeyQuestion2.What is theaccuracyofserologicscreeningforHSV-2
in asymptomatic adults, adolescents, and pregnant women?
We included 11 good- or fair-quality studies (n = 7129; range,
61-3290) assessing the accuracy of 1 or more type-specific HSV-2
serologic tests compared with Western blot.13-23 All 11 studies
enrolled adults and none enrolled pregnant women. Most studies
(8) enrolled a population with HSV-2 prevalence greater than
40% based on Western blot (range, 41%-70%). Two included
studies described whether participants had current or prior symp-
toms consistent with genital herpes17,30; 1 study enrolled US col-
lege students with no current or previous symptoms consistent
with genital herpes,30 and the other enrolled men seeking care at
US STI clinics (17% were later diagnosed with genital herpes).17 In
the 9 other studies, the proportion of participants who had cur-
rent or past symptoms of genital herpes was not described. Most
studies enrolled participants from 1 or more African countries; 3
were set in the United States,13,17,18 and 1 enrolled participants
from multiple countries (Argentina, Costa Rica, Korea, Mexico,
Nigeria, Thailand, and Vietnam).14
All 11 studies compared the FocusHerpeSelect HSV-2 enzyme-
linked immunosorbent assaywithWesternblot anduseda test cut-
point value of 1.1 to define a positive test result (current manufac-
turer’s cutpoint). Seven studies also assessed higher test cutpoints
to boost specificity (ranging from 2.1 to 3.5).14-16,19,21-23 Four stud-
ies alsoassessedaccuracyof thebiokitHSV-2RapidTest.18,20-22Fur-
ther study characteristics are shown in Table 1.
Ten studies (n = 6537 participants analyzed; range, 89-3290)
provided sufficient data to estimate sensitivity and specificity of
HerpeSelect using a cutpoint value of 1.113-16,18-23; individual study
Figure 2. Summary of Evidence Search and Selection
270 Excluded
63 Ineligible population
36 Ineligible comparator
31 Ineligible intervention
21 Ineligible study design
18 Ineligible screening test
10 Poor quality study
4 Non–English-language
50 Ineligible outcome
37 Not original research
3001 Excluded after review of
titles and abstracts
11 Studies included for
KQ2 (10 studies for
quantitative analysis)
1 Study included for KQ64 Studies included for KQ52 Studies included for KQ42 Studies included for KQ30 Studies included for KQ1
289 Full-text articles assessed
for eligibility
3290 Records screened
3213 Records identified through
database searching
(after duplicates removed)
77 Records identified through
other sources
17 Fair- or good-quality studies
(from 19 articles) included
KQ indicates key question.
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Table 1. Characteristics of Included Studies Assessing the Accuracy of Serologic Screening Tests for HSV-2 (Key Question 2)
Source
Analytic
Sample Size
Eligible
Serologic Tests Population
Recruitment
Setting;
Country
Age, Mean
(SD), y
Sex and Race,
%
STI
Comorbidity,
%
HSV-1
Positive, %
Study
Quality
Ashley-Morrow
et al,14 2004
675 HerpeSelect Women aged ≥15 y
participating
in an HSV
seroprevalence
study
Study
participants;
multinationala
NR Women: 100
Nonwhite: NR
NR 93-99 (by
WB)
Fair
Delany-
Moretlwe
et al,23 2010
98 HerpeSelect Adult women with
unknown HSV-2
serostatus
Family
planning
clinics;
South Africa
26 (range,
18-46)
Women: 100
Nonwhite: NR
52 (HIV-1) NR Fair
Golden et al,17
2005
61 HerpeSelect Men who had been
tested for HSV at
an STI clinic
between
2001-2002
2 county
STI clinics;
United States
Median,
35 (range,
18-73)
Women: 0
Nonwhite: 23
1 56 (by WB) Fair
Hogrefe
et al,19 2002
776 HerpeSelect Adults, varied by
location;
Kenya: women
enrolled in a
vitamin A study;
Uganda: (1)
serologic samples
from participants
in an HIV
seroprevalence
study, (2) samples
from HIV-negative
women South
Africa and Namibia:
samples initially
collected for HIV
screenings from
healthy, primarily
middle-income
individuals
Varied by
location—
primarily study
participants;
multiple
African
countriesb
NR Women: NR
Nonwhite: NR
NR 89-100 (by
WB)
Fair
Lingappa
et al,21 2010
467 HerpeSelect;
biokit HSV-2
Adults
participating in a
study of genital
herpes
seroprevalence and
incidence
Study
participants;
Uganda
NR Women: NR
Nonwhite: NR
12 (HIV-1) NR Good
Mark et al,13
2007; Mark
et al,30 2008
89 HerpeSelect Urban university
students with no
history of genital
herpes or genital
sores who reported
being sexually
active within the
past 6 mo
Recruited by
flyers,
announce-
ments, and
online/
newspaper
advertisements
at 1 university;
United States
25 (4.4) Women: 64
Nonwhite: 31
NR 9 (by
HerpeSelect);
3 (by WB)
Good
Morrow et al,18
2005
782 HerpeSelect;
biokit HSV-2
Two populations
enrolled: (1) adult
MSM screened for
enrollment in a
clinical trial
assessing acyclovir
to reduce HIV
transmission and
(2) consecutive
serologic samples
submitted for HSV
WB testing
Study
participants
and serologic
samples sent to
the University
of Washington
Virology
Laboratory
during a 4-wk
period; United
States
NR Women: 0
Nonwhite: NR
NR 64 (by WB) Fair
Mujugira
et al,15 2011
3290 HerpeSelect HIV-negative adult
men and women
participating in the
Partners in
Prevention
HSV/HIV
Transmission
Studyc
Study
participants;
multiple
African
Countriesd
Median, 34 Women: 33
Nonwhite: NR
NR NR Good
Ng’ayo et al,22
2010
233 HerpeSelect;
biokit HSV-2
Adult men who
worked in the
fishing industry
who reported being
sexually active in
the previous 2 wk
Community
(beaches along
Lake Victoria);
Kenya
NR (≥18 y
eligible)
Women: 0
Nonwhite: NR
NR NR Fair
(continued)
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results are shown in eTable 8 in the Supplement. Pooled estimates
of sensitivity and specificity were 99% (95% CI, 97%-100%) and
81% (95% CI, 68%-90%), respectively (Table 2). eFigure 1 in the
Supplement shows the HSROC with 95% confidence ellipse using
pairs of sensitivity and specificity. Estimates for specificity were
highly variable, ranging from 41% to 97.5%. Studies handled
equivocal (or indeterminate) test results in various ways, which
may contribute to heterogeneity in estimates of test accuracy
(eTable 8 in the Supplement). Five studies (n = 1840; range,
61-776) reported a positive predictive value using the manufactur-
er’s cutpoint; estimates ranged from 37.5 to 86.0.13,14,17,18,22 Four
studies (n = 1779; range, 89-776) reported negative predictive val-
ues; estimates ranged from 96.5 to 100.13,14,18,22
Seven studies (n = 5516 participants analyzed; range, 99-
3290)assessedhigher cutpoints for apositive test result than those
recommendedbythemanufacturer (ranging from2.2 to3.5) (eTable
8 in the Supplement).14-16,19,21-23 Estimates of specificity were gen-
erally higher at cutpoints greater than 2.2. The pooled estimates of
sensitivity and specificity were 95% (95% CI, 91%-97%) and 89%
(95% CI, 82%-93%), respectively (Table 2). eFigure 2 in the
Supplement shows the HSROC with 95% confidence ellipse using
pairs of sensitivity and specificity.
Four studies (n = 1512participants analyzed; range,98-782) re-
ported on the sensitivity and specificity of the biokit HSV-2 Rapid
Test (eTable 9 in the Supplement).18,20-22 The pooled estimates of
sensitivity and specificity were 84% (95% CI, 73%-91%) and 95%
(95% CI, 93%-97%), respectively (Table 2). eFigure 3 in the
Supplement shows the HSROC with 95% confidence ellipse using
pairs of sensitivity and specificity.
Harms of HSV-2 Serologic Screening
in Asymptomatic Populations
KeyQuestion3a.WhataretheharmsofserologicscreeningforHSV-2
or combined testing forHSV-1 andHSV-2 in asymptomaticnonpreg-
nant adolescents and adults?
Key Question 3b. What are the harms of serologic screening for
HSV-2 or combined testing for HSV-1 and HSV-2 in asymptomatic
pregnant women?
Characteristicsandoutcomesof the2 included fair-quality stud-
iesare shown ineTable 10 in theSupplement.24,25Bothstudieswere
set in the United States and assessed the effect of a positive HSV-2
serologic test result on psychosocial outcomes among peoplewho
reported no history of genital herpes.
The first study (n = 24) was a qualitative assessment of the
psychosocial effects of receiving an HSV-2 diagnosis based on
serologic testing.24 Investigators recruited 24 adult participants
reporting no history of genital herpes who tested HSV-2 seroposi-
tive by Western blot. Participants were recruited from clinical set-
tings (STI, maternal and infant care, family medicine, and research
clinics) and completed in-depth interviews on their experience of
Table 2. Accuracy of Serologic Screening Tests for HSV-2 ComparedWithWestern Blot (Key Question 2)a
HerpeSelect
biokit HSV-21.1 Cutpoint 2.2-3.5 Cutpoint
Studies, No. 10 7 4
Participants, No. 6537 5516 1512
Sensitivity (95% CI), % 99 (97-100) 95 (91-97) 84 (73-91)
Specificity (95% CI), % 81 (68-90) 89 (82-93) 95 (93-97)
Likelihood ratio (95% CI)
Positive 5 (3-10) 8 (5-13) 17 (11-29)
Negative 0.01 (0.003-0.04) 0.06 (0.036-0.099) 0.16 (0.92-0.30)
Abbreviation: HSV-2, herpes simplex
virus type 2.
a Values summarize the pooled
estimates of sensitivity and
specificity based on hierarchical
summary receiver operating
characteristic curve and bivariate
analyses.
Table 1. Characteristics of Included Studies Assessing the Accuracy of Serologic Screening Tests for HSV-2 (Key Question 2) (continued)
Source
Analytic
Sample Size
Eligible
Serologic Tests Population
Recruitment
Setting;
Country
Age, Mean
(SD), y
Sex and Race,
%
STI
Comorbidity,
%
HSV-1
Positive, %
Study
Quality
Smith et al,16
2009
99 HerpeSelect Adult HIV-negative
men participating
in a trial to
determine the
effectiveness of
circumcision in
reducing HIV
incidence
Study
participants
(recruited from
STI clinics,
workplaces,
and
community
organizations);
Kenya
NR Women: 0
Nonwhite: NR
NR NR Fair
Van Dyck
et al,20 2004
330 HerpeSelect;
biokitHSV-2
Adults who were
enrolled in a study
on factors
determining the
spread of HIV
Study
participants;
multiple
African
countriese
NR (15-49 y
eligible)
Women: NR
Nonwhite: NR
NR NR Fair
Abbreviations: HIV, human immunodeficiency virus; HSV, herpes simplex virus;
MSM, menwho have sex with men; NR, not reported; STI, sexually transmitted
infection; WB,Western blot.
a Argentina, Costa Rica, Korea, Mexico, Nigeria, Thailand, Vietnam.
bKenya, Uganda, South Africa, Namibia.
c Randomized trial of acyclovir (for HSV-2 suppressive therapy) to reduce HIV-1
transmission.
dKenya, Rwanda, Tanzania, Uganda, Botswana, South Africa, Zambia.
e Kenya, Zambia, Benin, Cameroon.
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HSV-2 diagnosis. The qualitative analysis identified 3 categories of
themes: (1) short-term, emotional responses that included surprise,
denial, confusion, distress, sadness, disappointment, and relief to
know; (2) short-term, psychological responses that included fear of
telling sex partners, anger at the source partner, guilt about acquir-
ing or transmitting, and concern about transmitting to a child; and
(3) perceived ongoing responses that included fear of telling future
partners, concern about transmitting to a sex partner, feeling sexu-
ally undesirable, feeling socially stigmatized, feeling like “damaged
goods,” sex avoidance because of social responsibility, fear of trans-
mitting to a newborn child, and relationship concerns relating to
the diagnosis. The authors concluded that participants exhibited
strong emotional and psychological responses to their serologic
diagnoses of HSV-2, while observing that some of these responses
were time limited.24
The second study (n = 33) enrolled individuals aged 14 to 30
years from an urban university setting and various clinical settings,
includingSTI, primary care, andadolescent clinics.25Of the 1190en-
rolled, 820 (68%) had serologic testing (type of test not de-
scribed) and 149 (18%)were HSV-2–positive. Of those participants
who screenedpositive forHSV-2, 93 (62%) returned for their initial
test results and33 returned for the3-month follow-up.At3months,
participants completed the herpes Health-Related Quality of Life
Questionnaire (HRQOLQ).31 Participants responded to each item
using a 4-point scale that ranged from “very” to “not at all.” For in-
dividual-item analysis, answers of “very” or “quite” were consid-
ered indicative of endorsing the experience.25 A number of indi-
vidualHRQOLQ itemswereendorsed frequentlyas “very”or “quite,”
including the following: “It is difficult to forget that I have herpes”
(63%); “Iworryaboutgivingherpes tosomeone” (56%);and“Iworry
about people finding out I have herpes” (48%).25Other items from
theHRQOLQendorsed less frequently are shown ineTable 10 in the
Supplement.
Effectiveness of Preventive Interventions
for Asymptomatic HSV-2–Seropositive Populations
Key Question 4.How effective are oral antiviral medications in re-
ducing genital HSV-2 viral shedding in asymptomatic adolescents,
adults, and pregnant women?
Weincluded2fair-qualityRCTs(n = 129; range,63-66)thatcom-
pared daily preventive antiviral medication with placebo over 6 to
8weeks (Table 3).26,27 One study did not describe how symptoms
of genital herpes were ascertained27; the other reported that par-
ticipants had undergoneHSV serologic testing as part of their clini-
cal care but reported no current or prior symptoms consistentwith
genital herpes.26OneRCT(n = 63)assessedvalacyclovir (1 gdaily)26
and theother (n = 66) assessed famciclovir (250mg twicedaily).27
In both studies, participants were educated on performing self-
administered swabs of the anogenital area, which they completed
once daily during the treatment period. Study characteristics are
shown in Table 3.
One RCT reported a statistically significant reduction in viral
shedding outcomes, and the other did not (Table 3). In the RCT
assessing valacyclovir (n = 63), valacyclovir treatment significantly
reduced subclinical days with HSV-2 shedding compared with pla-
cebo (1.5% vs 5.1%, P < .001) and also resulted in a greater propor-
tion of participants experiencing no days with shedding (84%
vs 54%, P = .001; between-group difference, 30% [95% CI,
15%-46%]).26 In the RCT comparing famciclovir (250 mg twice
daily) with placebo (n = 66), participants in both groups did not
have a significantly different risk of subclinical viral shedding; poly-
merase chain reaction samples were positive on 5.0% and 5.7% of
subclinical days, respectively (relative risk [RR], 0.8 [95% CI, 0.41-
1.56]; P = .52).27
Quality limitations across both trials included attrition (23%-
29%of participants) and unclear handling ofmissing data. In addi-
tion, the validity and reliability of daily self-swab to ascertain viral
shedding is unclear, potentially contributing tomeasurement bias.
KeyQuestion5a.Howeffectivearepreventivemedicationsandbe-
havioral counseling interventions in reducing future symptomatic
episodes and transmission of genital herpes in asymptomatic non-
pregnant adults and adolescents?
KeyQuestion5b.Howeffectivearepreventivemedicationsandbe-
havioral counseling interventions in reducing neonatal HSV infec-
tionandsymptomatic episodesofgenital herpesatdelivery inpreg-
nant women?
We included 4 fair-quality RCTs (n = 2550; range, 63-1484)
evaluating antiviralmedications (Table3).26-29Two focusedonpre-
venting transmission and enrolled adult heterosexual coupleswho
wereserologicallydiscordant forHSV-2 infection (ie,onepartnerhad
known genital herpes and the other partner had no prior diagnosis
and was also HSV-2 seronegative),28,29 and 2 enrolled asymptom-
atic adults with no history of genital herpes whowere seropositive
for HSV-2 infection.26,27
TwoRCTscomparingdaily suppressiveantiviralmedicationwith
placebo also reported viral shedding outcomes and were de-
scribed inKQ4.Both reportedon incidenceof genital herpes symp-
toms (Table 3). In the RCT assessing valacyclovir (n = 63), partici-
pantswere educated on signs and symptoms of genital herpes and
instructed to return to the clinic any time they suspected an out-
break. At 2months, fewer participants in the valacyclovir group re-
ported symptomsof genital herpes than in theplacebo group (12%
vs23%, respectively). The authors report that the treatment effect
was significant (P = .033, controlling for the crossover effect); how-
ever, thearithmeticmeanof thedifferencebetweengroupswasnot
significant (11%[95%CI,−0.6%to22%]).26 IntheRCTassessingfam-
ciclovir (n = 66), the incidenceofgenitalherpessymptomswassimi-
lar in thefamciclovirandplacebogroupsat6weeks(17.5%and17.2%,
respectively; P value not reported).27
Quality limitations across both trials included attrition (23%-
29% of participants), unclear handling of missing data, and risk of
measurement bias. Symptoms were ascertained by self-report
(not using a validated questionnaire) over a relatively short dura-
tion (6-8 weeks). One study enrolled participants who had HSV
serologic testing as part of their clinical care26; results may not be
applicable to those who screen positive but are not seeking test-
ing for HSV infection.
Two RCTs compared the benefit of daily suppressive antiviral
medication with placebo for preventing genital herpes transmis-
sionbetweenHSV-2–serodiscordantheterosexualcouples;onemea-
sured outcomes at 8months28,29 and the other at 12 to 24months
(Table3).32OneRCTenrolled immunocompetentcouples,28,29while
the otherwas a substudy of HIV-1–serodiscordant couples inwhich
theHIV-1–negativepartnerwasalsosusceptible toHSV-2.32OneRCT
(n = 1484 couples) assessed valacyclovir (500 mg daily),28,29 and
the other (n = 937 couples) assessed acyclovir (400 mg daily); in
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both studies, antiviral medication was provided to the infected
partner.32 Both studies were conducted in multiple countries; one
enrolled from 96 study sites in the United States, Canada, Europe,
Latin America, and Australia,28,29 and one was conducted in 7
sub-Saharan African countries.32
The 2 trials found conflicting results (Table 3). In the RCT
assessing valacyclovir, fewer HSV-2–susceptible partners in the
valacyclovir group had symptomatic HSV-2 infection than partners
randomized to placebo over 8 months (0.5% vs 2.2%, respec-
tively; hazard ratio, 0.25 [95% CI, 0.08-0.75]); similarly, fewer
HSV-2–suceptible partners in the valacyclovir group seroconverted
to HSV-2 than those in the placebo group (1.9% vs 3.6%, respec-
tively; P = .04; hazard ratio, 0.52 [95% CI, 0.27-0.99]).28,29
In contrast, the RCT assessing acyclovir use among HIV-1–
serodiscordant couples did not find a reduction in transmission.
At follow-up (median, 18 months), the number of susceptible part-
ners with seroconversions was not statistically different between
the acyclovir group (40) and placebo group (28), which indicated
seroincidence of 5.9 and 4.3 cases per 100 person-years, respec-
tively (hazard ratio, 1.35 [95% CI, 0.83-2.20]; P = .22).32
Key limitations across both trials included high attrition; 22%
ofcoupleswithdrewfromone trial,28,29 and theoverall attritionwas
66% in the other trial.32
Harms of Preventive Interventions
for Asymptomatic HSV-2–Seropositive Populations
KeyQuestion6a.Whatare theharmsofpreventivemedicationsand
behavioral counseling interventions for reducing future sympto-
matic episodes and transmission of genital herpes in asymptom-
atic nonpregnant adults and adolescents?
KeyQuestion6b.Whatare theharmsofpreventivemedicationsand
behavioral counseling interventions for reducing neonatal HSV in-
fection and symptomatic episodes of genital herpes at delivery in
asymptomatic pregnant women?
OneRCT(n = 63) included inKQ4andKQ5reportedonharms.26
Rates of reported adverse events were similar among groups ran-
domized to valacyclovir and placebo, including dizziness, head-
ache, and nausea (eTable 11 in the Supplement).26
Discussion
This reviewdidnot identifyanyeligible studiesdirectlyassessing the
benefits or harms of serologic screening for HSV-2 compared with
no screening. Therefore, the literature thatmight establish an indi-
rect chain of evidence from multiple questions that link screening
to health outcomes (KQ2 through KQ7) was reviewed.
Table 4 provides a summary of findings in this evidence
review. Estimates for specificity varied and were imprecise, with-
out a clear explanation for the observed heterogeneity. Potential
explanations for false-positive serologic test results include cross-
reactivity with HSV-1 (or other viruses), recent seroconversion,
geographic variability in HSV-2 strain variants, and laboratory
error. At higher cutpoints, estimates of sensitivity and specificity
from 8 studies in Africa were still imprecise. There was evidence
from 2 uncontrolled observational studies that detection of unex-
pected HSV-2 by screening is associated with potential psychoso-
cial harms, including anxiety, worry, and distress. Other potential
harms of serologic screening include false-positive results that
lead to psychosocial distress and costs of confirmatory testing.
The estimates of the accuracy of serologic tests are generally
applicable to populations with a higher prevalence of HSV-2 infec-
tion than general primary care populations in the United States.
The majority of studies assessing the accuracy of HerpeSelect
enrolled a population with HSV-2 prevalence greater than 40%
based on Western blot. Use of HerpeSelect in a population with
lower prevalence, similar to that of US adults, would greatly
increase the number of false-positive test results. For example, in a
hypothetical population of 100000 persons with a prevalence of
asymptomatic HSV-2 of 50% (similar to the prevalence in included
studies), with test sensitivity of 99% and specificity of 81%, there
would be an estimated 49 500 true-positive results and 9500
false-positive results (positive predictive value, 84%). If the preva-
lence instead were 16% (similar to the seroprevalence in the gen-
eral US adult population among people with unknown symptom
status), the number of true-positive results would be estimated at
15 840, and the number of false-positive results would be esti-
mated at 15 960 (positive predictive value, 50%). True-positive
results would decrease further, and false-positive results would
increase further if the prevalence were less than 16%.
If sensitivity were unchanged, screening a lower-prevalence
populationwould reduce thenumber of false-negative test results,
although thenegativepredictive valuewould change little. It is pos-
sible, however, that the sensitivity of the screening tests could be
lower in a lower-prevalence population, owing to such factors as
lower antibody levels, thus increasing the number of false-
negative results per 1000 persons tested. The direction of these
changes with prevalence would be similar regardless of which cut-
points were used.
There was limited evidence evaluating preventive interven-
tions for asymptomatic adults who screen positive for HSV-2.
No studies enrolled pregnant women or adolescents, and none
assessed behavioral counseling interventions. Two RCTs (total of
129 participants) assessed the benefit of preventive antiviral medi-
cations for reducing HSV-2 viral shedding and symptomatic occur-
rences among adults seropositive for HSV-2 who reported no prior
genital herpes symptoms. Evidence from these 2 trials does not
allow an accurate estimate of the benefit of preventive antiviral
medications for improving health outcomes. The 2 trials differed in
several ways. They assessed different medications (valacyclovir
and acyclovir), recruited from different sources, and used different
tests to establish HSV-2 infection. Both assessed outcomes over a
short time (6-8 weeks) and relied on self-report to ascertain symp-
tom occurrence. This duration is likely inadequate to evaluate
whether antiviral medications reduce symptom incidence among
populations who have been asymptomatic. Results were inconsis-
tent and imprecise; 1 trial found benefit for valacyclovir compared
with placebo for reducing viral shedding and symptom oc-
currences,26 and the other found no statistically significant differ-
ences between groups.27
Similarly, the 2 RCTs assessing preventive antiviral medica-
tions for reducingHSV-2 transmissionbetweenserodiscordantpart-
ners were heterogeneous and found inconsistent results. One en-
rolled immunocompetent couples from primarily industrialized
countries,28while theotherenrolledcouplesdiscordant forbothhu-
man immunodeficiencyvirus andHSV-2 fromsub-SaharanAfrica.32
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Table 4. Summary of Evidence: Serologic Screening for Genital Herpesa
Key Question
Topic
No. of
Studies
No. of
Participants Study Design
Summary of Findings (Including
Consistency and Precision) Applicability
Limitations (Including
Reporting Bias)
Key question 1:
Benefits of
screening
0 NA NA No studies were identified that directly
evaluated the benefits of screening
compared with no screening.
NA NA
Key question 2:
Accuracy of
serologic
screening tests
11 Total: 7129;
pooled
analyses:
6537
(HerpeSelect,
1.1 cutpoint);
5516
(HerpeSelect,
2.2-3.5
cutpoint);
1512 (biokit
HSV-2)
Cross-sectional Pooled sensitivity for detecting HSV-2 with
HerpeSelect (1.1 cutpoint) was 99% (95%
CI, 97%-100%) and slightly lower (95%) at
higher cutpoints. Pooled sensitivity of
biokit HSV-2 was 84% (95% CI, 73%-91%).
Pooled specificity for detecting HSV-2 with
HerpeSelect (at manufacturer’s cutpoint)
was 81% (95% CI, 68%-90%) and slightly
higher (89%) at higher cutpoints.
Pooled specificity of biokit HSV-2 was 95%
(95% CI, 93%-97%).
Overall, findings were consistent
but imprecise.
Populations from African
countries that have a
high prevalence of HSV-2
infection (>50%)
Evidence identified for
only 2 FDA-approved
HSV-2 serologic tests;
most studies excluded
equivocal test results
from calculations of test
accuracy (or did not
describe the handling
of missing data).
Key question 3:
Harms of
screening
2 57 Qualitative
study; cohort
study
The qualitative study found that
participants with a new HSV-2 diagnosis
had short-term emotional responses (eg,
distress, sadness), short-term
psychological responses (eg, fear of telling
sex partners), and perceived ongoing
responses (eg, feeling sexually
undesirable). The cohort study found that
individual items frequently reported as
interfering in daily life on the herpes
HRQOLQ included “It is difficult to forget I
have herpes” (63%); “I worry about giving
herpes to someone” (56%); “I worry about
people finding out I have herpes” (48%);
and others. Findings were consistent but
imprecise.
Asymptomatic persons
with no known history of
genital herpes
Studies are uncontrolled;
due to study design and
outcome measures,
estimating magnitude
of effect or assessing
precision is not possible.
Key question 4:
Benefits of
treatment:
shedding
2 129 Crossover RCTs The valacyclovir trial found that those
taking valacyclovir (1 g daily) had fewer
subclinical days with any genital HSV-2
viral shedding detected over 6-8 wk than
those taking placebo (1.5% vs 5.1%,
respectively, P < .001). The famciclovir
trial found that those taking famciclovir
(250 mg twice daily) had fewer subclinical
days with any genital HSV-2 viral shedding
detected over 6-8 wk than placebo (5.7%
vs 5.0%, respectively; RR, 0.8 [95% CI,
0.41-1.56]; P = .52). Findings were
inconsistent and imprecise.
Asymptomatic adults
with HSV-2 infection
diagnosed (or confirmed)
by Western blot
Studies assessed different
medications over a short
duration; sample sizes
were small, and overall
attrition was >20%
in both trials.
Key question 5:
Benefits of
treatment for
asymptomatic
adults
2 129 Crossover RCTs The valacyclovir trial found that those
taking valacyclovir (1 g daily) had lower
incidence of self-reported genital herpes
symptoms at 6-8 wk than placebo (12% vs
23%, respectively; P = .033). The
famciclovir trial found that those taking
famciclovir (250 mg twice daily) had lower
incidence of self-reported genital herpes
symptoms at 6-8 wk than those taking
placebo (17.5% vs 17.2%, respectively; P
value NR). Findings were inconsistent and
imprecise.
Asymptomatic adults
with HSV-2 infection
diagnosed (or confirmed)
by Western blot
Incidence was
self-reported; outcomes
were measured over a
relatively short duration;
sample sizes were small,
and overall attrition was
>20% in both trials.
Key question 5:
Benefits of
treatment for
serodiscordant
couples
2 2421 RCTs The valacyclovir trial found that
participants whose partners took
valacyclovir (1 g daily) had lower incidence
of HSV-2 seroconversion at 32 wk than
those whose partners took placebo (HR,
0.52 [95% CI, 0.27-0.99]; P = .04). The
acyclovir trial found that participants
whose partners took acyclovir had no
difference in incidence of HSV-2
seroconversion at 78 wk compared with
those whose partners took placebo (HR,
1.35 [95% CI, 0.83-2.20]; P = .220).
Findings were inconsistent and imprecise.
Asymptomatic adults
with known, ongoing
exposure to genital
herpes from a partner
Studies assessed different
medications over different
durations in populations
that were heterogeneous.
Key question 6:
Harms of
treatment
1 62 RCT Incidence of self-reported adverse events
were similar between groups (headache,
nausea). Findings were imprecise;
consistency NA.
Generally healthy
asymptomatic
nonpregnant adults
Unclear if adverse events
were prespecified.
Abbreviations: FDA, US Food and Drug Administration; HR, hazard ratio; HRQOLQ, Health-Related Quality of Life Questionnaire; HSV, herpes simplex virus;
NA, not applicable; NR, not reported; RCT, randomized clinical trial; RR, relative risk.
a Quality of evidence was fair for all studies in this table.
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The trials assessed different medications (valacylovir and acyclo-
vir) and over different durations (8 months and a median of 18
months).One trial foundbenefit for valacyclovir comparedwithpla-
cebo for reducing symptomaticHSV-2 infectionandHSV-2 serocon-
version in the susceptible partner; however, themagnitudeof ben-
efit for symptomreductionwasmodest, and resultswere imprecise
(0.5% vs 2.2%, respectively; hazard ratio, 0.25 [95% CI, 0.08-
0.75]).
One trial assessed harms ofmedications; adverse events were
similar between groups randomized to valacyclovir and placebo.26
Other review studies have concluded that there are few harms in
nonpregnant adults.34
This review had limitations. Studies were required to com-
pare an FDA-approved currently available serologic screening test
with Western blot. We did not evaluate other comparisons, such
as a serologic test compared with a viral polymerase chain reac-
tion swab or culture or with another commercially available sero-
logic test, to determine concordance. We limited the assessment
to studies enrolling people with no current or prior symptoms and
found only 2 trials. For people with frequent symptomatic recur-
rences of genital herpes (more than 4 episodes per year), antiviral
medications have been shown to reduce the frequency of recur-
rences; however, the magnitude of effect is uncertain, and the
quality of evidence is low. A Cochrane review published in 2014
evaluated the efficacy of antiviral medications (acyclovir, famci-
clovir, and valacyclovir) to suppress genital herpes outbreaks in
nonpregnant adults34; 22 trials were included, and the risk of bias
was considered high for half of the studies and unclear for the
other half. The authors concluded that there was low-quality evi-
dence that the risk of having at least 1 clinical recurrence was
reduced with acyclovir (9 parallel-group trials, n = 2049; RR, 0.48
[95% CI, 0.39-0.58]), valacyclovir (4 trials, n = 1788; RR, 0.41
[95% CI, 0.24-0.69]), or famciclovir (2 trials, n = 732; pooled RR,
0.57 [95% CI, 0.50-0.64]).34 It is unclear whether these results
would apply to people who have less frequent recurrences (or
who are asymptomatic).
Conclusions
Serologic screening for genital herpes is associatedwith a high rate
of false-positive test results and potential psychosocial harms. Evi-
dence from RCTs does not establish whether preventive antiviral
medication for asymptomatic HSV-2 infection has benefit.
ARTICLE INFORMATION
Author Contributions:Dr Feltner had full access to
all of the data in the study and takes responsibility
for the integrity of the data and the accuracy of the
data analysis.
Concept and design: Feltner, Grodensky, Ebel,
Ashok, Jonas.
Acquisition, analysis, or interpretation of data:
Feltner, Grodensky, Ebel, Middleton, Harris, Ashok,
Jonas.
Drafting of the manuscript: Feltner, Grodensky,
Ebel, Middleton, Ashok, Jonas.
Critical revision of the manuscript for important
intellectual content: Feltner, Grodensky, Ebel,
Harris, Ashok, Jonas.
Statistical analysis: Feltner.
Obtained funding: Feltner, Jonas.
Administrative, technical, or material support:
Grodensky, Ebel, Middleton, Jonas.
Supervision: Feltner, Jonas.
Conflict of Interest Disclosures: All authors have
completed and submitted ICMJE Form for
Disclosure of Potential Conflicts of Interest and
none were reported.
Funding/Support: This research was funded
under contract HHSA-290-2012-00015-I,
Task Order No. 6, from the Agency for Healthcare
Research and Quality (AHRQ), US Department of
Health and Human Services, under a contract to
support the USPSTF.
Role of the Funder/Sponsor: Investigators worked
with USPSTFmembers and AHRQ staff to develop
the scope, analytic framework, and key questions
for this review. AHRQ had no role in study selection,
quality assessment, or synthesis. AHRQ staff
provided project oversight; reviewed the report to
ensure that the analysis met methodological
standards, and distributed the draft for peer review.
Otherwise, AHRQ had no role in the conduct of the
study; collection, management, analysis, and
interpretation of the data; and preparation, review,
or approval of themanuscript findings. The
opinions expressed in this document are those of
the authors and do not reflect the official position
of AHRQ or the US Department of Health and
Human Services.
Additional Contributions:We gratefully
acknowledge the following individuals
for their contributions to this project: David
Meyers, MD (AHRQ), EvelynWhitlock, MD, MPH
(Kaiser Permanente Research Affiliates EPC), and
Meera Viswanathan, PhD; Carol Woodell, BSPH;
Rachel Weber, PhD; Christiane Voisin, MSLS;
Sharon Barrell, MA; and Loraine Monroe
(RTI International–University of
North Carolina EPC).
Additional Information: A draft version of the full
evidence report underwent external peer review
from 4 content experts (Rhoda A. Morrow, PhD,
University of Washington, Seattle; David Kimberlin,
MD, University of Alabama at Birmingham; Jeffrey
Peipert, MD, MPH, MHA,Washington University,
St Louis, MO; and 1 anonymous content expert) and
4 partner reviewers from the Eunice Kennedy
Shriver National Institute of Child Health and
Human Development; National Institute of Allergy
and Infectious Diseases; National Center for HIV,
Hepatitis, STD, and TB Prevention (Centers for
Disease Control and Prevention); and Office of the
Surgeon General, G-3/5/7, Health andWellness.
Comments from reviewers were presented
to the USPSTF during its deliberation of the
evidence and were considered in preparing
the final evidence review.
Editorial Disclaimer: This evidence report is
presented as a document in support of the
accompanying USPSTF Recommendation
Statement. It did not undergo additional peer
review after submission to JAMA.
REFERENCES
1. Patel R, Rompalo A. Genital herpes infections.
In: Zenilman JM, ShahmaneshM, eds. Sexually
Transmitted Infections: Diagnosis, Management,
and Treatment. Sudbury, MA: Jones & Bartlett
Learning; 2009:165-176.
2. Wald A, Zeh J, Selke S, et al. Reactivation of
genital herpes simplex virus type 2 infection in
asymptomatic seropositive persons.N Engl J Med.
2000;342(12):844-850.
3. Sacks SL. Famciclovir suppression of
asymptomatic and symptomatic recurrent
anogenital herpes simplex virus shedding in
women: a randomized, double-blind,
double-dummy, placebo-controlled, parallel-group,
single-center trial. J Infect Dis. 2004;189(8):1341-1347.
4. Whitley RJ, Kimberlin DW, Roizman B. Herpes
simplex viruses. Clin Infect Dis. 1998;26(3):541-553.
5. Workowski KA. Centers for Disease Control and
Prevention sexually transmitted diseases treatment
guidelines. Clin Infect Dis. 2015;61(suppl 8):S759-
S762.
6. Bradley H, Markowitz LE, Gibson T,
McQuillan GM. Seroprevalence of herpes simplex
virus types 1 and 2—United States, 1999-2010.
J Infect Dis. 2014;209(3):325-333.
7. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J,
Corey L. Effect of serologic status and cesarean
delivery on transmission rates of herpes simplex
virus frommother to infant. JAMA. 2003;289(2):
203-209.
8. LeGoff J, Péré H, Bélec L. Diagnosis of genital
herpes simplex virus infection in the clinical
laboratory. Virol J. 2014;11:83.
9. US Preventive Services Task Force. Screening for
genital herpes: recommendation statement. Am
Fam Physician. 2005;72(8):1557-1561. http://www
.aafp.org/afp/2005/1015/p1557.html. Accessed
November 16, 2016.
10. US Preventive Services Task Force. Methods
and Processes: section 3: topic work plan
development. https://www
.uspreventiveservicestaskforce.org/Page/Name
/methods-and-processes. Updated August 2016.
Accessed November 4, 2016.
Clinical Review& Education US Preventive Services Task Force Evidence Report: Serologic Screening for Genital Herpes
2542 JAMA December 20, 2016 Volume 316, Number 23 (Reprinted) jama.com
Downloaded From: https://jamanetwork.com/ by a University Of North Carolina - Chapel Hill User  on 08/14/2019
Copyright 2016 American Medical Association. All rights reserved.
11. West SL, Gartlehner G, Mansfield AJ, et al.
Comparative Effectiveness ReviewMethods: Clinical
Heterogeneity. Rockville, MD: Agency for Healthcare
Research and Quality; 2010.
12. StataCorp. Stata Statistical Software: Release 14.0.
College Station, TX: StataCorp LP; 2015.
13. Mark HD, Nanda JP, Roberts J, Rompalo A,
Melendez JH, Zenilman J. Performance of focus
ELISA tests for HSV-1 and HSV-2 antibodies among
university students with no history of genital
herpes. Sex Transm Dis. 2007;34(9):681-685.
14. Ashley-Morrow R, Nollkamper J, Robinson NJ,
Bishop N, Smith J. Performance of focus ELISA tests
for herpes simplex virus type 1 (HSV-1) and HSV-2
antibodies among women in ten diverse
geographical locations. Clin Microbiol Infect. 2004;
10(6):530-536.
15. Mujugira A, Morrow RA, Celum C, et al; Partners
in Prevention HSV/HIV Transmission Study Team.
Performance of the Focus HerpeSelect-2 enzyme
immunoassay for the detection of herpes simplex
virus type 2 antibodies in seven African countries.
Sex Transm Infect. 2011;87(3):238-241.
16. Smith JS, Bailey RC, Westreich DJ, et al.
Herpes simplex virus type 2 antibody detection
performance in Kisumu, Kenya, using the
Herpeselect ELISA, Kalon ELISA, Western blot and
inhibition testing. Sex Transm Infect. 2009;85(2):
92-96.
17. GoldenMR, Ashley-Morrow R, Swenson P,
HogrefeWR, Handsfield HH,Wald A. Herpes
simplex virus type 2 (HSV-2) Western blot
confirmatory testing amongmen testing positive
for HSV-2 using the Focus enzyme-linked
immunosorbent assay in a sexually transmitted
disease clinic. Sex Transm Dis. 2005;32(12):771-777.
18. Morrow RA, Friedrich D, Meier A, Corey L.
Use of “biokit HSV-2 Rapid Assay” to improve the
positive predictive value of Focus HerpeSelect
HSV-2 ELISA. BMC Infect Dis. 2005;5:84.
19. HogrefeW, Su X, Song J, Ashley R, Kong L.
Detection of herpes simplex virus type 2–specific
immunoglobulin G antibodies in African sera by
using recombinant gG2, Western blotting, and gG2
inhibition. J Clin Microbiol. 2002;40(10):3635-3640.
20. van Dyck E, Buvé A, Weiss HA, et al.
Performance of commercially available enzyme
immunoassays for detection of antibodies against
herpes simplex virus type 2 in African populations.
J Clin Microbiol. 2004;42(7):2961-2965.
21. Lingappa J, Nakku-Joloba E, Magaret A, et al.
Sensitivity and specificity of herpes simplex virus-2
serological assays among HIV-infected and
uninfected urban Ugandans. Int J STD AIDS. 2010;21
(9):611-616.
22. Ng’ayoMO, Friedrich D, Holmes KK, Bukusi E,
Morrow RA. Performance of HSV-2 type specific
serological tests in men in Kenya. J Virol Methods.
2010;163(2):276-281.
23. Delany-Moretlwe S, Jentsch U, Weiss H, et al.
Comparison of Focus HerpesSelect and Kalon
HSV-2 gG2 ELISA serological assays to detect
herpes simplex virus type 2 antibodies in
a South African population. Sex Transm Infect.
2010;86(1):46-50.
24. Melville J, Sniffen S, Crosby R, et al.
Psychosocial impact of serological diagnosis of
herpes simplex virus type 2: a qualitative
assessment. Sex Transm Infect. 2003;79(4):280-285.
25. Rosenthal SL, Zimet GD, Leichliter JS, et al.
The psychosocial impact of serological diagnosis of
asymptomatic herpes simplex virus type 2
infection. Sex Transm Infect. 2006;82(2):154-157.
26. Sperling RS, Fife KH,Warren TJ, Dix LP,
Brennan CA. The effect of daily valacyclovir
suppression on herpes simplex virus type 2 viral
shedding in HSV-2 seropositive subjects without a
history of genital herpes. Sex Transm Dis. 2008;35
(3):286-290.
27. Leone P, Warren T, Hamed K, Fife K, Wald A.
Famciclovir reduces viral mucosal shedding in
HSV-seropositive persons. Sex Transm Dis. 2007;34
(11):900-907.
28. Corey L, Wald A, Patel R, et al; Valacyclovir HSV
Transmission Study Group. Once-daily valacyclovir
to reduce the risk of transmission of genital herpes.
N Engl J Med. 2004;350(1):11-20.
29. Kim HN,Wald A, Harris J, Almekinder J,
Heitman C, Corey L. Does frequency of genital
herpes recurrences predict risk of transmission?
further analysis of the valacyclovir transmission
study. Sex Transm Dis. 2008;35(2):124-128.
30. Mark H, Nanda JP, Joffe A, et al. Serologic
screening for herpes simplex virus among university
students: a pilot study. J Am Coll Health. 2008;57
(3):291-296.
31. Wild D, Patrick D, Johnson E, Berzon R, Wald A.
Measuring health-related quality of life in persons
with genital herpes.Qual Life Res. 1995;4(6):532-539.
32. Mujugira A, Magaret AS, Celum C, et al;
Partners in Prevention HSV/HIV Transmission Study
Team. Daily acyclovir to decrease herpes simplex
virus type 2 (HSV-2) transmission fromHSV-2/HIV-1
coinfected persons: a randomized controlled trial.
J Infect Dis. 2013;208(9):1366-1374.
33. Celum C,Wald A, Lingappa JR, et al; Partners in
Prevention HSV/HIV Transmission Study Team.
Acyclovir and transmission of HIV-1 from persons
infected with HIV-1 and HSV-2. N Engl J Med. 2010;
362(5):427-439.
34. Le Cleach L, Trinquart L, Do G, et al. Oral
antiviral therapy for prevention of genital herpes
outbreaks in immunocompetent and nonpregnant
patients. Cochrane Database Syst Rev. 2014;8(8):
CD009036.
Evidence Report: Serologic Screening for Genital Herpes US Preventive Services Task Force Clinical Review& Education
jama.com (Reprinted) JAMA December 20, 2016 Volume 316, Number 23 2543
Downloaded From: https://jamanetwork.com/ by a University Of North Carolina - Chapel Hill User  on 08/14/2019
